About The Charles Bronfman Institute for Personalized Medicine
Mount Sinai created The Charles Bronfman Institute for Personalized Medicine (IPM) to drive innovation in the data-driven and gene-based individualization of healthcare. The Institute’s groundbreaking work led to the creation of the BioMe Biobank Program to enable innovation in personalized healthcare. Over 23,000 Mount Sinai patients have enrolled in the BioMe program, which helps them receive more targeted, personalized care in real-time – based on their own DNA – through Mount Sinai’s electronic medical record (EMR) system. Our EMR-linked personalized medicine system empowers participating BioMe patients by providing tailored information in data-driven, gene-based personalized healthcare. This information includes each enrolled patient’s unique genetic information and clinical data.
Mount Sinai patients who enroll in the BioMe program also contribute to medical breakthroughs by consenting to make their DNA, genetic and clinical information available for medical research in a secure and de-identified manner.
IPM also provides participating healthcare professionals with education, tools and resources for up-to-date practice guidelines incorporating the latest gene-based information for personalized healthcare.
1468 Madison Avenue
(at E. 101st Street)
18th Floor, Room 18-16
New York, NY 10029
“The future of medicine lies in genomics research and translating it to the bedside – and Mount Sinai’s commitment to translational research makes us uniquely poised to lead that revolution. With its unique and highly innovative translational programs, The Charles Bronfman Institute for Personalized Medicine is a significant achievement for Mount Sinai, propelling us to the forefront of personalized medicine and its application in the clinical setting,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn School of Medicine and the Executive Vice President for Academic Affairs of The Mount Sinai Health System.